You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameForasartan
Accession NumberDB01342
TypeSmall Molecule
GroupsExperimental
DescriptionForasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • SC-52458
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII065F7WPT0B
CAS number145216-43-9
WeightAverage: 416.522
Monoisotopic: 416.243692936
Chemical FormulaC23H28N8
InChI KeyYONOBYIBNBCDSJ-UHFFFAOYSA-N
InChI
InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30)
IUPAC Name
5-[(dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]pyridine
SMILES
CCCCC1=NN(CC2=CN=C(C=C2)C2=CC=CC=C2C2=NNN=N2)C(CCCC)=N1
Pharmacology
IndicationFor the treatment of hypertension.
Structured Indications Not Available
PharmacodynamicsForasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. By inhibiting angiotensin II receptors, this drug leads to a decrease in sodium reabsorption (which decreases water content of blood) and a decrease in vasoconstriction. Combined, this has the effect of lowering blood pressure.
Mechanism of actionForasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. Also, since angiotensin causes vasoconstriction, the inhibition of this receptor decreases vasoconstriction, which consequently also decreases vascular resistnace.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Forasartan Action PathwayDrug actionSMP00160
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacThe risk or severity of adverse effects can be increased when Forasartan is combined with Aceclofenac.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Forasartan is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Forasartan is combined with Adapalene.Approved
AliskirenAliskiren may increase the hyperkalemic activities of Forasartan.Approved, Investigational
AmilorideForasartan may increase the hyperkalemic activities of Amiloride.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Forasartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Forasartan is combined with Antipyrine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Forasartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Forasartan.Approved, Withdrawn
AzapropazoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Forasartan is combined with Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Forasartan is combined with Balsalazide.Approved, Investigational
BemiparinBemiparin may increase the hyperkalemic activities of Forasartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Benazepril.Approved, Investigational
BenoxaprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Benoxaprofen.Withdrawn
Betulinic AcidThe risk or severity of adverse effects can be increased when Forasartan is combined with Betulinic Acid.Investigational
BromfenacThe risk or severity of adverse effects can be increased when Forasartan is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Forasartan is combined with Bucillamine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Forasartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Forasartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Captopril.Approved
CarprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Forasartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Celecoxib.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Forasartan.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Forasartan is combined with Chloroquine.Approved, Vet Approved
CilazaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Cilazapril.Approved
CiprofloxacinForasartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClonixinThe risk or severity of adverse effects can be increased when Forasartan is combined with Clonixin.Approved
CurcuminThe risk or severity of adverse effects can be increased when Forasartan is combined with Curcumin.Investigational
CyclosporineForasartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Forasartan is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Forasartan.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Forasartan.Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Forasartan is combined with Diclofenac.Approved, Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Forasartan is combined with Diflunisal.Approved
DrospirenoneForasartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Forasartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Forasartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Forasartan is combined with Ebselen.Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Forasartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Forasartan.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Forasartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Forasartan.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Forasartan is combined with Etanercept.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Forasartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Forasartan is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Forasartan is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Forasartan is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Forasartan is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Fenoprofen.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Forasartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Forasartan is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Fosinopril.Approved
HeparinHeparin may increase the hyperkalemic activities of Forasartan.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Forasartan is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Forasartan is combined with HMPL-004.Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Forasartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Forasartan is combined with Icatibant.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Imidapril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Forasartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Indoprofen.Withdrawn
IsoxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Isoxicam.Withdrawn
KebuzoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Forasartan is combined with Ketorolac.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Forasartan is combined with Leflunomide.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Forasartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Forasartan.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Lornoxicam.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Forasartan is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Forasartan is combined with Masoprocol.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Forasartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Forasartan is combined with Metamizole.Withdrawn
MizoribineThe risk or severity of adverse effects can be increased when Forasartan is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Moexipril.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Nabumetone.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Forasartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Forasartan is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Forasartan is combined with Naftifine.Approved
NaproxenThe risk or severity of adverse effects can be increased when Forasartan is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Forasartan is combined with NCX 4016.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Forasartan is combined with Nepafenac.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Forasartan.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Forasartan is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Forasartan is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Forasartan is combined with Nitroaspirin.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Forasartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Forasartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Forasartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Forasartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxaprozin.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxyphenbutazone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Parecoxib.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Forasartan.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Perindopril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Forasartan is combined with Pimecrolimus.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Forasartan is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Piroxicam.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Forasartan is combined with Propacetamol.Approved
PTC299The risk or severity of adverse effects can be increased when Forasartan is combined with PTC299.Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Forasartan is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Forasartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Forasartan.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Rofecoxib.Investigational, Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Forasartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Forasartan is combined with Salsalate.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Forasartan is combined with Seratrodast.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Spirapril.Approved
SpironolactoneForasartan may increase the hyperkalemic activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Forasartan is combined with SRT501.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Forasartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Forasartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Suprofen.Approved, Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Temocapril.Experimental, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Forasartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Forasartan is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Forasartan is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Forasartan is combined with Tiaprofenic acid.Approved
TinoridineThe risk or severity of adverse effects can be increased when Forasartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Forasartan.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Forasartan is combined with Tolmetin.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Forasartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Forasartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Forasartan is combined with Tranilast.Approved, Investigational
TriamtereneForasartan may increase the hyperkalemic activities of Triamterene.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Forasartan.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Forasartan is combined with Trisalicylate-choline.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Forasartan is combined with Valdecoxib.Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Forasartan is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Forasartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Forasartan is combined with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9069
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.615
P-glycoprotein inhibitor INon-inhibitor0.6612
P-glycoprotein inhibitor IINon-inhibitor0.8805
Renal organic cation transporterInhibitor0.5228
CYP450 2C9 substrateNon-substrate0.7854
CYP450 2D6 substrateNon-substrate0.831
CYP450 3A4 substrateNon-substrate0.5512
CYP450 1A2 substrateNon-inhibitor0.64
CYP450 2C9 inhibitorNon-inhibitor0.5115
CYP450 2D6 inhibitorNon-inhibitor0.7168
CYP450 2C19 inhibitorInhibitor0.7661
CYP450 3A4 inhibitorInhibitor0.6576
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7192
Ames testNon AMES toxic0.5233
CarcinogenicityNon-carcinogens0.8243
BiodegradationNot ready biodegradable0.9969
Rat acute toxicity2.7970 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6462
hERG inhibition (predictor II)Non-inhibitor0.546
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00667 mg/mLALOGPS
logP4.51ALOGPS
logP5.89ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)7.35ChemAxon
pKa (Strongest Basic)3.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area98.06 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity145.44 m3·mol-1ChemAxon
Polarizability46.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPhenylpyridines
Direct ParentPhenylpyridines
Alternative Parents
Substituents
  • 2-phenylpyridine
  • Phenyltetrazole
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Tetrazole
  • Azole
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Tokunaga R, Kushiku K, Yamada K, Yamada H, Furukawa T: Possible involvement of calcium-calmodulin pathways in the positive chronotropic response to angiotensin II on the canine cardiac sympathetic ganglia. Jpn J Pharmacol. 2001 Aug;86(4):381-9. [PubMed:11569611 ]
  2. Usune S, Furukawa T: Effects of SC-52458, a new nonpeptide angiotensin II receptor antagonist, on increase in cytoplasmic Ca2+ concentrations and contraction induced by angiotensin II and K(+)-depolarization in guinea-pig taenia coli. Gen Pharmacol. 1996 Oct;27(7):1179-85. [PubMed:8981065 ]
  3. Hagmann M, Nussberger J, Naudin RB, Burns TS, Karim A, Waeber B, Brunner HR: SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. J Cardiovasc Pharmacol. 1997 Apr;29(4):444-50. [PubMed:9156352 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:11 / Updated on October 14, 2016 13:14